Literature DB >> 11251013

Reliability and validity of the functional assessment of cancer therapy-ovarian.

K Basen-Engquist1, D Bodurka-Bevers, M A Fitzgerald, K Webster, D Cella, S Hu, D M Gershenson.   

Abstract

PURPOSE: To report the reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) in a consecutive series of outpatients with epithelial ovarian cancer. PATIENTS AND METHODS: Two hundred thirty-two ovarian cancer patients attending an outpatient gynecologic oncology clinic completed questionnaires at baseline. The patients' FACT-O scores were compared with their performance status, disease stage, treatment status, and other factors hypothesized to be related to quality of life. Patients received a second questionnaire either one week after baseline to assess the instrument's test-retest reliability and/or two months after baseline to evaluate its sensitivity to change in performance status.
RESULTS: Internal consistency and test-retest reliability of the FACT-O were adequate. Overall, the scales correlated with other measures as expected; all correlations were in the hypothesized direction. Patients with advanced disease, poor performance status, and who were receiving active treatment had lower scores on physical, functional, and ovarian cancer-specific scales. The total FACT-O and emotional well-being scores were lower for patients with poor performance status and patients in active treatment. The FACT-O total and all subscale scores except emotional well-being were sensitive to decreases in performance status.
CONCLUSION: Overall, the FACT-O provides a reliable and valid assessment of the quality of life of women with ovarian cancer, and is appropriate as a brief quality of life assessment in clinical trials and descriptive studies.

Entities:  

Mesh:

Year:  2001        PMID: 11251013     DOI: 10.1200/JCO.2001.19.6.1809

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  80 in total

1.  A new index of priority symptoms in advanced ovarian cancer.

Authors:  Sally E Jensen; Sarah K Rosenbloom; Jennifer L Beaumont; Amy Abernethy; Paul B Jacobsen; Karen Syrjala; David Cella
Journal:  Gynecol Oncol       Date:  2010-11-13       Impact factor: 5.482

2.  Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

Authors:  Vivian E von Gruenigen; Helen Q Huang; Jan H Beumer; Heather A Lankes; William Tew; Thomas Herzog; Arti Hurria; Robert S Mannel; Tina Rizack; Lisa M Landrum; Peter G Rose; Ritu Salani; William H Bradley; Thomas J Rutherford; Robert V Higgins; Angeles Alvarez Secord; Gini Fleming
Journal:  Gynecol Oncol       Date:  2017-01-13       Impact factor: 5.482

3.  Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  Lari Wenzel; Helen Q Huang; Bradley J Monk; Peter G Rose; David Cella
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

4.  A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study.

Authors:  Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Gibbons; Bradley J Monk; Peter G Rose; Deborah K Armstrong; David Cella; Lari Wenzel
Journal:  J Pain Symptom Manage       Date:  2010-05       Impact factor: 3.612

5.  Surgical versus medical treatment for ocular surface squamous neoplasia: A quality of life comparison.

Authors:  Carolina L Mercado; Cameron Pole; James Wong; Juan F Batlle; Fabiola Roque; Noah Shaikh; Juan C Murillo; Anat Galor; Carol L Karp
Journal:  Ocul Surf       Date:  2018-09-11       Impact factor: 5.033

6.  Social support among women who died of ovarian cancer.

Authors:  Jody M Jackson; Sharon J Rolnick; Steve S Coughlin; Christine Neslund-Dudas; Mark C Hornbrook; Jeanne Darbinian; Donald J Bachman; Lisa J Herrinton
Journal:  Support Care Cancer       Date:  2006-12-20       Impact factor: 3.603

Review 7.  Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: a reliability generalization.

Authors:  David Victorson; Joshua Barocas; Juliette Song; David Cella
Journal:  Qual Life Res       Date:  2008-10-08       Impact factor: 4.147

8.  Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients.

Authors:  Susan K Lutgendorf; George M Slavich; Koenraad Degeest; Michael Goodheart; David Bender; Premal H Thaker; Frank Penedo; Bridget Zimmerman; Joseph Lucci; Luis Mendez; Katherine Collins; Anil K Sood
Journal:  Gynecol Oncol       Date:  2013-10-03       Impact factor: 5.482

9.  Patient preferences in advanced or recurrent ovarian cancer.

Authors:  Laura J Havrilesky; Angeles Alvarez Secord; Jessie A Ehrisman; Andrew Berchuck; Fidel A Valea; Paula S Lee; Stephanie L Gaillard; Greg P Samsa; David Cella; Kevin P Weinfurt; Amy P Abernethy; Shelby D Reed
Journal:  Cancer       Date:  2014-08-04       Impact factor: 6.860

10.  A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.

Authors:  Michelle K Wilson; Michael L Friedlander; Florence Joly; Amit M Oza
Journal:  Oncologist       Date:  2017-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.